Get the Daily Brief
Latest Biotech News
Illumina’s constellation mapping spots hard‑to‑see variants in pilot
In a GeneDx pilot presented at ASHG, Illumina’s constellation mapped‑read technology outperformed other methods at detecting challenging, hard‑to‑map variants implicated in rare disease. The pilot...
PacBio cuts per‑genome cost with reusable cells and new chemistry
Pacific Biosciences announced Sprq‑Nx chemistry and a program to reuse SMRT cell consumables for high‑volume customers, aiming to lower long‑read whole‑genome costs to roughly $250–$300 per genome...
RPI membrane outperforms columns for mRNA purification
Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose membrane with peptide ligands that outperformed commercial chromatography columns for purifying mRNA therapeutics....
Create Medicines rebrands, expands in‑vivo mRNA immune programming
Myeloid Therapeutics announced a rebrand to Create Medicines and broadened its platform beyond myeloid programming to include in‑vivo mRNA‑based programming of T cells and NK cells using lipid...
DeepSomatic delivers cross‑platform somatic variant calling and benchmarks
A team published DeepSomatic in Nature Biotechnology as a somatic small‑variant caller that works across short‑ and long‑read sequencing technologies and released seven public somatic variant...
Novo Nordisk bets $2.1B on Omeros’ MASP‑3 drug
Novo Nordisk agreed to license global rights to Omeros’ MASP‑3 antibody zaltenibart, committing up to $2.1 billion in milestones and royalties. The deal gives Novo immediate control of a mid‑stage...
Tubulis smashes European Series C records – funds ADC expansion
Tubulis closed a major Series C financing (reported in euros) to accelerate clinical development of its next‑generation antibody‑drug conjugates (ADCs). The round—among the largest European...
Kailera secures $600M — global Phase 3 push for obesity shot
Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable metabolic candidate that targets two pathways similar to marketed...
Pelage raises $120M as regenerative hair‑loss gel heads to phase III
Pelage Pharmaceuticals closed a $120 million Series B oversubscribed by GV and Arch Venture Partners to support PP‑405, a topical regenerative therapeutic aimed at activating dormant hair‑follicle...
Aicuris’ pritelivir clears Phase 3 — FDA filing set for 2026
Privately held Aicuris reported Phase 3 success for pritelivir, an oral antiviral for refractory herpes infections, announcing that patients on the drug outperformed standard‑of‑care in the trial....
Illumina’s constellation reads: GeneDx pilot spots hard‑to‑see variants
Illumina’s new constellation map read technology was trialed with GeneDx to detect difficult‑to‑map genomic variants in rare‑disease samples. The pilot reportedly exceeded alternative methods in...
PacBio drives down genome costs — reusable SMRT cells target sub‑$300 genomes
Pacific Biosciences announced a new chemistry and a program to allow select customers to reuse SMRT cells, aiming to lower per‑genome consumable costs for large sequencing projects. PacBio...
RPI membrane outperforms chromatography — faster, cleaner mRNA purification
Researchers at Rensselaer Polytechnic Institute developed a regenerated cellulose membrane with peptide ligands that outperformed commercial chromatography columns for mRNA purification. The team...
Tempus wins $60M ARPA‑H contract for AI cancer biomarker work
The U.S. Department of Health and Human Services awarded Tempus AI a $60 million ARPA‑H contract to support testing and research using biomarkers to create adaptive treatment strategies for...
Create Medicines expands beyond myeloid programming — rebrands and broadens pipeline
Myeloid Therapeutics rebranded as Create Medicines and announced an expanded strategy to program multiple immune lineages in vivo using an mRNA‑LNP platform. The company said the pivot will add T...
Novo Nordisk bets $2.1B on Omeros’ MASP‑3 antibody: rare disease play
Novo Nordisk agreed to acquire global rights to zaltenibart, an Omeros antibody that inhibits MASP‑3, in a deal worth up to $2.1 billion including milestones. Novo will fund pivotal testing in...
Tubulis pulls record European series C — ADC program fueled for expansion
Antibody‑drug conjugate specialist Tubulis closed a €308 million (≈$356M) Series C to expand clinical development of TUB‑040 and its ADC platform. The funding positions the company to test its...
Kailera nets $600M to take Zepbound‑like obesity shot into global phase 3
Kailera Therapeutics closed a $600 million Series B led by Bain Capital PE to advance KAI‑9531, a weekly injectable targeting the same receptors as market leader GLP‑1/GIP agents, into global...
BioCryst snaps up Astria for $700M — doubles down on hereditary angioedema
BioCryst agreed to acquire Astria Therapeutics for roughly $700 million in cash and stock to add Astria’s long‑acting injectable navenibart to its hereditary angioedema (HAE) portfolio. The deal...
Long‑read sequencing: PacBio cuts genome costs with reusable SMRT cells
Pacific Biosciences unveiled a program enabling reuse of SMRT cell consumables and launched a new Sprq‑Nx chemistry that raises output and adds 5‑hydroxymethylcytosine detection. PacBio says...